News and Events

Press Releases

May 09, 2017

Muse bio appoints genomics industry expert, John Stuelpnagel, as Chairman of the Board of Directors

Boulder, CO – May 09, 2017 – Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced Dr. John Stuelpnagel, co-founder, first CEO and former COO of Illumina and a well-known genomics industry entrepreneur, will become Chairman of Muse bio’s Board of Directors. In addition to Illumina, Dr. Stuelpnagel has co-founded and held senior leadership roles in several life science companies and brings extensive knowledge in building successful enterprises and commercializing disruptive technologies.

February 28, 2017

Muse bio secures $23M Series B financing led by Venrock

Genome engineering company assembles world-class investor syndicate to advance development of its gene editing and single-cell writing technology

Boulder CO – February 28, 2017 - Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.

December 15, 2016

Nature Biotechnology paper details high-throughput, multiplexed CRISPR technology

Revolutionary technology licensed by Muse bio enables precise, genome-wide engineering

Boulder, CO – December 15, 2016 – Muse bio today announced the publication of a paper in Nature Biotechnology describing, for the first time, its foundational technology platform that enables rational engineering of the whole genome with single-nucleotide precision.

December 7, 2016

Muse bio appoints proven biotech industry executive and innovator, Kevin Ness, as CEO

Kevin Ness brings expertise in commercializing innovative products for the biotechnology industry

Boulder CO - December 7, 2016 - Muse bio, a privately-held company leading the development of next-generation genome engineering technologies, today announced that Dr. Kevin Ness has been appointed Chief Executive Officer and member of the Board of Directors.